ライフサイエンスコーパス: renal failure

1 , damage to the glycocalyx, proteinuria, and renal failure.

2 r cardiovascular disease events, stroke, and renal failure.

3 y is an important cause of acute and chronic renal failure.

4 loop that regulates FGF23 expression during renal failure.

5 quently, the G3YR adult mice suffered severe renal failure.

6 onic kidney disease progression to end-stage renal failure.

7 nib group died from drug-related hepatic and renal failure.

8 tokine TNF are likely to provoke episodes of renal failure.

9 were normal, but she had rapidly progressive renal failure.

10 of diabetes mellitus and possibly of chronic renal failure.

11 optimum form of vascular access in end-stage renal failure.

12 thic hemolytic anemia, thrombocytopenia, and renal failure.

13 re phenotype showing progressive hepatic and renal failure.

14 etween ages 2.7 and 28 years, typically from renal failure.

15 ; the most common of these effects was acute renal failure.

16 ation is the optimum treatment for end-stage renal failure.

17 ses the risk for developing hypertension and renal failure.

18 linical problem that can result in end-stage renal failure.

19 neumonia, peritonitis, severe arrhythmia, or renal failure.

20 tinopathy, new or worsening albuminuria, and renal failure.

21 tous vascular calcification in patients with renal failure.

22 ures, auditory or visual hallucinations, and renal failure.

23 and in the kidney, it predicts the onset of renal failure.

24 uld be dedicated to preventing postoperative renal failure.

25 in glomeruli from dogs with clinical VL and renal failure.

26 on, bleeding or transfusion event, and acute renal failure.

27 he kidney and, in some cases, progression to renal failure.

28 fe-threatening genetic disease that leads to renal failure.

29 SRNS regularly progresses to end-stage renal failure.

30 failure, myocardial infarction, and chronic renal failure.

31 e loss of podocytes, glomerulosclerosis, and renal failure.

32 (ADPKD) is the most common genetic cause of renal failure.

33 hypertension, proteinuria, and in some cases renal failure.

34 laise, weakness, hepatitis, weight loss, and renal failure.

35 art failure, cardiac arrhythmias and chronic renal failure.

36 lomerulonephritis (GN), which often leads to renal failure.

37 ineural deafness and progressive hepatic and renal failure.

38 d their dysfunction leads to proteinuria and renal failure.

39 e loss, albuminuria, glomerulosclerosis, and renal failure.

40 s crucial for inducing FGF23 production upon renal failure.

41 yield the long-term mortality from liver and renal failure.

42 ts with renal insufficiency or patients with renal failure.

43 5- to 4-fold higher risk of developing acute renal failure.

44 nt, and patients often progress to end-stage renal failure.

45 ed tubular epithelial injury, apoptosis, and renal failure.

46 pleuropericardial effusion, hypotension, and renal failure.

47 Renal cystic diseases are a leading cause of renal failure.

48 er 6 months of age and children with chronic renal failure.

49 a common cause of childhood hypertension and renal failure.

50 essive tubulointerstitial fibrosis (TIF) and renal failure.

51 limited, but suggested an increased risk of renal failure.

52 osis (dRTA) may lead to nephrocalcinosis and renal failure.

53 ADPKD) is the most frequent genetic cause of renal failure.

54 ect that leads to progressive juvenile-onset renal failure.

55 s essential for the progression to end-stage renal failure.

56 ute kidney injury that can lead to end-stage renal failure.

57 long bones regulates FGF23 production during renal failure.

58 thrombotic microangiopathy (TMA) that causes renal failure.

59 and decreasing proportion of respiratory and renal failure.

60 t frequently causes ureteral obstruction and renal failure.

61 SHPT is a frequent consequence of chronic renal failure.

62 lyte disorders, 0.25 (95% CI, 0.12-0.39) for renal failure, 0.24 (95% CI, 0.09-0.39) for urinary trac

63 lyte disorders, 1.14 (95% CI, 1.06-1.23) for renal failure, 1.10 (95% CI, 1.04-1.16) for urinary trac

64 95% confidence interval [CI], 1.00-1.94) for renal failure, 1.34 (95% CI, 0.96-1.86) for shock durati

65 ever, confusion, rash, thrombocytopenia, and renal failure, 10 days after a hunting trip in the Nevad

66 rrhage (1.6% versus 0.2%; P=0.03), and acute renal failure (13.9% versus 9.4%; P=0.02) were significa

67 ypertension [90.4% versus 82.5%] and chronic renal failure [14.4% versus 7.6%]).

68 d to treatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyr

69 , for stroke 26%, for heart failure 37%, for renal failure 28%, and for all-cause mortality 35%.

70 The most common complication was acute renal failure (30.44% of cases).

71 ory support-related complications were acute renal failure 41%, bleeding 25%, neurologic damage in su

72 (14 [2.0%] and 15 [2.2%], P=0.79), and acute renal failure (42 [6.1%] and 35 [5.1%], P=0.45).

73 th a very high mortality in other subgroups: renal failure (43%), AR<grade 2 at baseline (31%), low t

74 th (2.3%, 0.8%, and 0.6%; P = .02) and acute renal failure (6.2%, 7.6%, and 2.4%; P < .001) after ASA

75 1%), valvular heart disease (5.0%-9.8%), and renal failure (7.1%-19.6%; P<0.001 for all).

76 One example is acute renal failure, a major cause of morbidity and mortality

77 ed by kidney antibrush border antibodies and renal failure (ABBA disease).

78 were confirmed in two independent models of renal failure, adenine diet induced and 5/6 nephrectomy.

79 levant risk factors, including age, sex, and renal failure (adjusted hazard ratio 2.08; 95% confidenc

80 Acute renal failure (adjusted odds ratio [AOR], 3.01; 95% conf

81 ry artery disease, rupture, or postoperative renal failure (all Ps < 0.05), but not treatment failure

82 gest the possibility of stratifying risk for renal failure among lithium-treated patients.

83 genesis, ranks as one of the major causes of renal failure among the pediatric population.

84 attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions).

85 , pneumonia, myocardial infarction, or acute renal failure and a length of stay >75th percentile), re

86 , myocardial infarction, pneumonia, or acute renal failure and a length of stay >75th percentile).

87 ing ischemia-reperfusion (IR) injury reduces renal failure and application of 8-pCPT-2'-O-Me-cAMP pro

88 , a severe multisystem presentation (chronic renal failure and cardiomyopathy) in infancy.

89 r-recognized condition and a risk factor for renal failure and cardiovascular disease.

90 (PKDs) are genetic disorders that can cause renal failure and death in children and adults.

91 wer to assess clinical safety events such as renal failure and fractures, our data suggest that E/C/F

92 .51), of which 28% was explained by comorbid renal failure and hazardous alcohol use.

93 s were strongest between ED visits for acute renal failure and heat waves defined by maximum apparent

94 e entity, is known to present as progressive renal failure and its leading presentation with scrotal

95 s glomeruli and progresses towards end stage renal failure and multiple organ dysfunction.

96 ute respiratory distress syndrome, steroids, renal failure and need for vasopressors).

97 and severe long term complications, notably renal failure and neurological impairment.

98 Both donors had renal failure and pretransplant renal biopsies showing 1

99 ve AAGN patients who had developed end-stage renal failure and received a kidney allograft in 1 of 6

100 The primary events were renal (incident renal failure and renal replacement therapy [RRT]) and b

101 or these conditions and included unspecified renal failure and reported disorders of kidney dysfuncti

102 and urinary sepsis in one patient, and acute renal failure and respiratory failure in one patient) we

103 Renal failure and the need for repeat TAVR, although les

104 le-treated I/R injury which exhibited severe renal failure and tubular damage at 24 hours.

105 ignificant protection from I/R-induced acute renal failure and tubular damage.

106 is associated with a high long-term risk for renal failure and urothelial cancer, and the potential w

107 erstitial nephritis culminating in end-stage renal failure and urothelial malignancy.

108 ospital AF relapse and comorbidities such as renal failure and valvular heart disease are independent

109 eumonia, myelodysplastic syndrome, and acute renal failure) and two in the treatment of physician's c

110 ve pulmonary disease, diabetes mellitus, and renal failure), and a history of coronary artery bypass

111 e events (myasthenia gravis and worsening of renal failure), and one patient who received nivolumab 3

112 Recipient diagnosis, disease severity, renal failure, and ages of recipient and donor should be

113 ronary heart disease, stroke, heart failure, renal failure, and all-cause mortality.

114 cells in asthma, kidney epithelial cells in renal failure, and cortical and hippocampal neurons in b

115 and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treat

116 and consequences, such as metabolic disease, renal failure, and heart failure.

117 t for diagnosis of acalculous cholecystitis, renal failure, and interstitial and parenchymal lung dis

118 -year-old man presented with proteinuria and renal failure, and kidney biopsy analysis showed a nodul

119 Safety end points were in-hospital stroke, renal failure, and major bleeding.

120 , smoking, diabetes, liver disease, obesity, renal failure, and malnutrition showed good discriminati

121 is, encephalopathy, bacteremia/sepsis, acute renal failure, and myocarditis were rare (each </= 2% of

122 pital events (death, stroke, bleeding, acute renal failure, and need for permanent pacemaker) were ex

123 n obvious cause, and may include fever, mild renal failure, and neurologic deficits.

124 ng congenital bilateral cataracts, glaucoma, renal failure, and neurological impairments.

125 ey fibrosis contributes greatly to end-stage renal failure, and no specific treatment is available to

126 particularly involving calcium homeostasis), renal failure, and possibly, mortality.

127 luding myocardial infarction, heart failure, renal failure, and stroke.

128 lusion criteria were cardiovascular disease, renal failure, and the use of medications that affect th

129 therapy include: hypertension, proteinuria, renal failure, and thrombotic microangiopathy.

130 which would put them at risk for cardiac or renal failure, and thus represented a poor-risk group.

131 female; more often had diabetes mellitus and renal failure; and received less aggressive intervention

132 odeficiency infection; acute and unspecified renal failure; and septicemia (HCV only).

133 re associated with renal cysts and premature renal failure are commonly the result of mutations in th

134 of postoperative 180-day mortality and acute renal failure (ARF), improving upon predictions that rel

135 Several members of a family died from renal failure as a result of systemic amyloidosis.

136 rbidities such as valvular heart disease and renal failure as well as an early AF relapse were also p

137 Compound 8 also effectively attenuated renal failure, as measured by BUN levels in mice fed an

138 mechanisms of drug metabolism in hepatic and renal failure, as well as posttransplant drug-drug inter

139 verely debilitating for patients, leading to renal failure at young age.

140 may reduce the risk of short-term mortality, renal failure, atrial fibrillation, bleeding, and length

141 re (beta, 20 min; CI, 14-25; p < 0.001), and renal failure (beta, 16 min; CI, 10-22; p < 0.001).

142 PGF and other postoperative events, such as renal failure, biopsy-proven rejection, and stroke.

143 acute neurological symptoms in patients with renal failure, blood pressure fluctuations, use of cytot

144 as associated with an increased incidence of renal failure but not with faster reversal of shock or i

145 ger and less likely to have heart or chronic renal failure, but they were more likely to receive mech

146 epithelial cell proliferations, and died of renal failure by 3 mo of age.

147 iciency was identified using the presence of renal failure by ICD9 code or laboratory-confirmed glome

148 ly required in 1.4% of the patients, 19% had renal failure by RIFLE (Risk, Injury, Failure) criteria.

149 End stage renal failure can be seen very rare.

150 analyzed included diabetes mellitus, chronic renal failure, cardiovascular events, NLR-NAR cancer, bo

151 0.024) and decline in the hazard of chronic renal failure close to the threshold of significance (sH

152 hould be closely monitored for patients with renal failure, concomitant aspirin use, and poor INR con

153 ted into WT recipients (n=7) developed acute renal failure (control group), WT grafts transplanted in

154 was calculated by assigning 1 point each for renal failure, coronary artery disease, diabetes mellitu

155 Chronic renal failure (CRF) is a major public health problem wor

156 erbilirubinemia and/or Encephalopathy and/or Renal Failure dataset with adoption of the Chronic Liver

157 Incidence of acute renal failure decreased in the PBM cohort (2.39% vs 1.67

158 hemodialysis, or nondialysis who experienced renal failure developed NSF after administration of gado

159 HNF1B mutations develop progressive chronic renal failure, diabetes mellitus (40-50%), and liver tes

160 populations with chronic conditions such as renal failure, diabetes, HIV and alcohol abuse.

161 We correlated data with the degree of renal failure (dialysis or nondialysis), prior immunosup

162 a with a history of hypertension and chronic renal failure due to renal artery occlusion was treated

163 Acute tubular damage is a major cause of renal failure, especially at the early phase of kidney t

164 Eleven patients (24%) had end-stage renal failure (ESRF) at presentation; of these, 3 had re

165 particularly in splenectomized cases, acute renal failure, Evans syndrome, and multitreatment (4 or

166 otection even in the unfavourable context of renal failure, extending the evidence for an important c

167 d to determine the cause or reversibility of renal failure for patients with end-stage liver disease

168 ts died, including 3 who had respiratory and renal failure, for a mortality of 18.5%.

169 ical history was also complicated by stage 4 renal failure from long-standing type II diabetes, hyper

170 val benefit, no increase in stroke, and less renal failure from treatment with transcatheter AVR comp

171 Renal failure has an unexpectedly low incidence but is a

172 ection that can progress to life-threatening renal failure has remained as a serious global health co

173 O-MRSA were more likely to have a history of renal failure, hemodialysis, residence in a long-term-ca

174 most frequently observed conditions included renal failure, hepatocellular injury, infections, and he

175 In chronic renal failure, higher circulating AGE levels result from

176 human diseases with eventual development of renal failure; however, effective treatment is lacking.

177 of upper limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism, or even symptoms of

178 In renal failure, hyperphosphatemia occurs despite a marked

179 These mice exhibited different severities of renal failure, hypertension, and glomerular lesions, acc

180 higher rates of infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia t

181 initiation time and baseline heart failure, renal failure, hypotension, acute kidney injury, altered

182 Cryptosporidiosis was complicated by renal failure in 15 patients.

183 erative renal cyst growth and progression to renal failure in autosomal dominant polycystic kidney di

184 US), which is the most common cause of acute renal failure in children in the United States.

185 nt regimes, it is important to remember that renal failure in conjunction with sickle cell disease do

186 s hemorrhagic diarrhea and potentially fatal renal failure in humans.

187 onium excretion is associated with death and renal failure in hypertensive kidney disease, even among

188 Thus, we induced renal failure in mice with targeted deletion of Klotho i

189 proximal tubular dysfunction and progressive renal failure in nephropathic cystinosis are largely unc

190 osis associated with massive proteinuria and renal failure in the absence of diabetic milieu or hyper

191 y (DN) became the leading cause of end-stage renal failure in the Western world.

192 pment of HUS, complications (ie, oligoanuric renal failure, involvement of the central nervous system

193 Renal failure is a key feature of HUS and a major cause

194 Classic calciphylaxis associated with renal failure is a life-threatening disease.

195 threatening complication directly related to renal failure is a subject of debate.

196 strategies for any PH type in patients with renal failure is largely unproven.

197 of developing upper urinary tract damage and renal failure is much lower in patients with slowly prog

198 Renal failure is the most significant organ dysfunction

199 0-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was l

200 end point was a composite of death or severe renal failure leading to renal-replacement therapy withi

201 ractory ascites, with a history of OHE or of renal failure, lower hemoglobin level, or MHE as diagnos

202 s, this series suggests that respiratory and renal failure may occur in severe Ebola virus disease, e

203 pulation, may help elucidate the etiology of renal failure, may predict post-LAT kidney function, and

204 Before the onset of renal failure, mice overexpressing RFS-kappaLCs showed P

205 In a chronic renal failure model, Phd(2/3)hKO mice maintained normal

206 ave been a successful therapy in several rat renal failure models.

207 nfection (n = 768), 25.3 to 30.6% in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid ar

208 mpared the T cell phenotype in children with renal failure (n=80) with that in healthy children (n=20

209 OR, 9.45; 95% CI, 3.41-26.18; P < .001), new renal failure necessitating dialysis (OR, 14.48; 95% CI,

210 Conclusion In the absence of known renal failure, neonates receiving standard inpatient car

211 It may contribute to the renal failure observed in nonsurviving patients.

212 ccal sepsis, toxic epidermal necrolysis, and renal failure) occurred at doses exceeding the MTDs.

213 erval [CI], 1.78-5.13; P<0.001), and chronic renal failure (odds ratio, 2.73; 95% CI, 1.60-4.70; P<0.

214 injury (odds ratio, 26.5; 95% CI, 7.3-96.6), renal failure (odds ratio, 3.6; 95% CI, 1.4-9.3), arrhyt

215 nts in the sunitinib group (one case each of renal failure, oesophageal varices haemorrhage, circulat

216 r advisory (OR, 1.354; 95% CI, 1.196-1.533), renal failure on dialysis (OR, 1.342; 95% CI, 1.123-1.60

217 The effect of renal failure on HDL properties is unknown.

218 eactive oxygen species (ROS), produced under renal failure or nephrotoxic drugs, may influence renal

219 onary disease (OR, 1.33; 95% CI, 1.27-1.39); renal failure (OR, 1.26; 95% CI, 1.18-1.36); diabetes (O

220 ke (OR, 1.64; 95% CI, 0.98-2.72; P=0.06) and renal failure (OR, 1.30; 95% CI, 0.98-1.72; P=0.06), wit

221 8.6; 95% CI, 3.9-18.8; P < .001), and acute renal failure (OR, 10.5; 95% CI, 3.8-29.3; P < .001).

222 R, 9.03; 95% CI, 3.49-23.38; P<0.001), acute renal failure (OR, 3.61; 95% CI, 1.68-7.75; P=0.001), an

223 embolism (OR:2.11; 95% CI: 1.70-2.61), acute renal failure (OR: 1.34; 95% CI; 1.22-1.47), and sepsis

224 llin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nephrotoxicity"] and registered meta-

225 llin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nephrotoxicity"] and registered meta-

226 dial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after

227 dial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after

228 luded presentation with rupture, preexisting renal failure, or intervention on the arch aorta (all Ps

229 ctions of age, sex, ischemic cardiomyopathy, renal failure, or QRS duration were not significant.

230 or morbidity (ie, myocardial injury, stroke, renal failure, or respiratory failure) within 30 days, b

231 had an increased risk of dialysis-dependent renal failure (P < 0.05).

232 ancy (non-Hodgkin's lymphoma, leukemia), and renal failure (P </= 0.03 for all).

233 ntation, but the increasing prevalence among renal failure patients has forced some centers to carefu

234 e PLA2R, is more highly expressed in chronic renal failure patients than in controls.

235 at were deemed unrelated to alectinib: acute renal failure; pleural effusion and pericardial effusion

236 Notably, acute renal failure predicted worse outcomes and performing an

237 ate that, prior to transplant, patients with renal failure present with heterogeneous levels of IgG h

238 ronic obstructive pulmonary disease, chronic renal failure, previous invasive coronary strategy, and

239 aneous remission (P=0.03) and lower rates of renal failure progression (P=0.002) and ESRD (P=0.01) du

240 in 2; postinterventional stroke, progressive renal failure, progressive heart failure, or combination

241 teroid use, coronary artery disease, chronic renal failure, pulmonary disease)] and preoperatively ca

242 ology in approximately half of patients with renal failure receiving dialysis.

243 ions between current smoking and deaths from renal failure (relative risk, 2.0; 95% confidence interv

244 ritis or interstitial nephritis, as cause of renal failure, represented the only predictive factor fo

245 h EBOV RNA levels, developed respiratory and renal failure requiring critical care support, and died.

246 vs. 3.5% surgery; p = 0.88), but the rate of renal failure requiring dialysis >30 days was lower in t

247 Renal failure requiring renal replacement therapy (RRT)

248 spiratory distress syndrome (ARDS) and acute renal failure, requiring mechanical ventilation, vasopre

249 romised patients with HIV infection, chronic renal failure, rheumatoid arthritis, solid-organ or stem

250 e events (RR: 1.02; 95% CI: 0.94 to 1.09) or renal failure (RR: 1.81; 95% CI: 0.86 to 3.80) between t

251 sults, except for an increase in the risk of renal failure (RR: 2.03; 95% CI: 1.30 to 3.18) with inte

252 At a median follow-up of 4.9 years, chronic renal failure, RRT, all fractures, hip fractures, and ve

253 ciated with failure to rescue included acute renal failure, septic shock, and postoperative pulmonary

254 use and the number of days alive and free of renal failure, shock, and death, all on day 14.

255 d bacteremia, pulmonary complications, acute renal failure, shock, intensive care unit admission, nee

256 rmed with no conversion to midsternotomy, no renal failure, strokes, or operative mortality (<30 days

257 y controlled systemic symptoms and prevented renal failure, suggesting that this treatment can signif

258 ts in the LIMP-2 gene cause action myoclonus-renal failure syndrome and also have been linked to PD.

259 nt of multiple renal cysts, often leading to renal failure that cannot be prevented by a current trea

260 kidney disease (ADPKD) is a common cause of renal failure that is due to mutations in two genes, PKD

261 found no increase in the incidence of acute renal failure, the frequency of intensive care unit admi

262 peristalsis are a leading cause of pediatric renal failure, the mechanisms underlying renal pacemaker

263 In end-stage renal failure, the net clinical benefit of VKAs in dialy

264 ;Tsp1 DKO mice did progress toward end-stage renal failure, their kidneys exhibited distinct histopat

265 cebo, was associated with fewer days free of renal failure to day 14 (10.1+/-5.3 vs. 11.0+/-4.7, P=0.

266 threatening complication directly related to renal failure to either an early or a delayed strategy o

267 Exclusion criteria were acute renal failure, trauma, and surgery within 2 days.

268 erbilirubinemia and/or Encephalopathy and/or Renal Failure trial by applying the recently introduced

269 erbilirubinemia and/or Encephalopathy and/or Renal Failure trial.

270 Twenty-two patients with T1D and end-stage renal failure undergoing islet transplantation were comp

271 ath, myocardial infarction, stroke, or acute renal failure up to the time of hospital discharge.

272 ization for fluid and electrolyte disorders, renal failure, urinary tract infection, septicemia, and

273 ization for fluid and electrolyte disorders, renal failure, urinary tract infection, septicemia, and

274 The prevalence of CKD and of renal failure vary worldwide, yet parallel increases in

275 Index acute renal failure was associated with increased odds of card

276 (range, 1-41) years in 77 patients, chronic renal failure was detected in 19 patients (25%): one req

277 ricular heterotopias, echogenic kidneys, and renal failure was homozygous for p.Arg633Trp in CRB2.

278 here the protection from postoperative acute renal failure was no greater than in mice with MASP-2 de

279 However, the effect on renal failure was not significant (0.95, 0.84-1.07).

280 In the latter patient, acute renal failure was not suspected to be related to everoli

281 mbolism of 4.90% (4.43-5.37), and those with renal failure were at higher risk of intracranial bleedi

282 ongestive heart failure, or chronic or acute renal failure were identified as high-risk patient subgr

283 outcomes other than stroke, retinopathy, and renal failure were lower in studies with greater baselin

284 critical care management for respiratory and renal failure were needed; 81.5% of these patients who r

285 ria, proteinuria >/=1 g/d, hypertension, and renal failure were observed in 97.4%, 84.8%, 85.3%, and

286 ure), and safety (serious adverse events and renal failure) were evaluated.

287 observed in vitamin D deficiency and chronic renal failure, where concentrations of the active vitami

288 cement therapy (CRRT) benefits patients with renal failure who are too hemodynamically unstable for i

289 alanced fluids: in-hospital mortality, acute renal failure with and without dialysis, and hospital an

290 myocardial infarction, stroke, or new-onset renal failure with dialysis by hospital discharge or by

291 myocardial infarction, stroke, or new-onset renal failure with dialysis, with less blood transfused.

292 hemolytic anemia, thrombocytopenia and acute renal failure with multiple organ involvement.

293 icant differences in the prevalence of acute renal failure (with and without dialysis) or in-hospital

294 cantly later with comorbid heart failure and renal failure, with absence of fever or hypotension, and

295 diomyopathy, ischemic heart disease; chronic renal failure, with and without dialysis; hepatitis and

296 cisplatin at 2 mg/kg induced KIN that led to renal failure within 5 weeks in Fan1(-/-) mice but not i

297 phthisis, typically progressing to end-stage renal failure within the first two decades of life, thus

298 sangial IgA1 deposits, is a leading cause of renal failure worldwide.

299 eature of HUS and a major cause of childhood renal failure worldwide.

300 hisis (NPHP) is the major cause of pediatric renal failure, yet the disease remains poorly understood